サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1445541

前立腺癌診断市場の評価：診断技術・癌タイプ・エンドユーザー・地域別の機会および予測 (2017～2031年)

Prostate Cancer Diagnostics Market Assessment, By Diagnostic Technique, By Cancer Type, By End-user, By Region, Opportunities and Forecast, 2017-2031F

出版日
ページ情報
英文 227 Pages
納期
3～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
前立腺癌診断市場の評価：診断技術・癌タイプ・エンドユーザー・地域別の機会および予測 (2017～2031年)
出版日: 2024年03月07日
発行: Market Xcel - Markets and Data
ページ情報: 英文 227 Pages
納期: 3～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の前立腺癌診断の市場規模は、2024年から2031年の予測期間中にCAGR 7.26％を記録し、2023年の63億1,000万米ドルから、2031年には110億5,000万米ドルの規模に成長すると予測されています。

世界の前立腺癌診断の市場は、さまざまな要因によって形成されています。これにはAIなどの技術の進歩、投資の増加、バイオマーカー検査の優位性、腺癌診断のためのツール、前立腺癌に対する意識の高まりなどが含まれます。

技術の進歩

世界の前立腺癌診断の市場の拡大にはAIをはじめとする技術の進歩が大きく影響しています。診断におけるAIの使用は、前立腺癌の検出効率と精度を向上させます。AIアルゴリズムは大きなデータセットを調べることで人間の目では気づかないような前立腺癌の特定の兆候を検出することができます。これは、AIアルゴリズムが従来の戦略よりも迅速かつ適切に癌を診断することを可能にします。この能力は、タイムリーな介入を行えるため、早期予後に極めて重要です。AIの使用は前立腺癌診断の分野で革命を起こし、患者の転帰を改善し、企業の成長を加速させています。

投資の増加

世界の前立腺癌診断の市場は新しいアイデアの創出を促すために企業や団体から資金提供を受けています。前立腺癌を検出するための新たな戦略やR&D努力を強化する技術開発を可能にするためには、資金へのアクセスが必要です。AIを活用した診断プラットフォームや高度なバイオマーカー検査など、新たな手法の開発や既存の手法の改良を支援するための投資が行われており、これらは業界を前進させる上で重要な役割を果たしています。投資の増加は技術革新に拍車をかけ、前立腺癌診断のための旧式の技術からの脱却に役立ちます。

バイオマーカー検査が提供する利点

前立腺癌の診断が飛躍的に増加しているのは、主にバイオマーカー検査の需要が高まっているためです。バイオマーカー検査はもっとも一般的に使用されている手法であり、その多くの利点によりますます人気が高まっています。これらの検査は高感度で特異的であるため、前立腺癌に関連するタンパク質や遺伝子を特定することができます。即座に対応できるため、症状が現れる前でも早期発見が可能です。さらに、バイオマーカー検査は、癌の攻撃性や治療に対する反応性に関する重要な情報を提供することで、オーダーメイドの治療戦略の開発できる可能性があります。需要の増加は、前立腺癌の検出と治療に対するバイオマーカー検査の効率と精度によるものです。

腺癌診断のためのツール

世界の前立腺癌診断の市場は、前立腺癌の多様な形態、特に流行している腺癌を検出するために設計された革新的な機器の導入よって、急成長を経験しています。これらの機器は、分子診断や高度な画像診断などの最先端技術を活用し、腺癌の正確な同定と特徴付けを行います。これは臨床的に大きな利点となります。腫瘍の位置、大きさ、範囲に関する詳細な情報を武器に、医師は高度に的を絞った治療計画を立てることができ、患者の転帰を最適化することができます。これらの特殊な診断ツールは、前立腺癌管理の成功の礎石と考えられている、早期かつ正確な発見という重要なニーズに応えるものです。

当レポートでは、世界の前立腺癌診断の市場を調査し、市場の定義と概要、市場規模の推移・予測、各種区分・地域別の詳細分析、産業構造、市場成長への影響因子の分析、ケーススタディ、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 調査手法

第2章 プロジェクトの範囲と定義

第3章 エグゼクティブサマリー

第4章 世界の前立腺癌診断市場の展望

  • 市場規模・予測
  • 診断技術別
    • 画像検査
    • 生検
    • バイオマーカー検査
    • 免疫組織化学
    • その他
  • 癌タイプ別
    • 扁平上皮癌
    • 小細胞前立腺癌
    • 腺癌
    • 移行上皮癌
    • その他
  • エンドユーザー別
    • 病院
    • 癌研究機関
    • 診断センター
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋
    • 南米
    • 中東・アフリカ
  • 企業別市場シェア

第5章 世界の前立腺癌診断市場の展望：地域別

  • 北米
  • 欧州
  • アジア太平洋
  • 南米
  • 中東・アフリカ

第6章 市場マッピング

  • 診断技術別
  • 癌タイプ別
  • エンドユーザー別
  • 地域別

第7章 マクロ環境と産業構造

  • 需要供給分析
  • 輸出入分析
  • バリューチェーン分析
  • PESTEL分析
  • ポーターのファイブフォース分析

第8章 市場力学

  • 成長促進要因
  • 成長抑制要因（課題、抑制要因）

第9章 規制の枠組みとイノベーション

  • 臨床試験
  • 特許の情勢
  • 規制当局の承認
  • イノベーション/新興技術

第10章 主要企業の情勢

  • 市場リーダー上位5社の競合マトリックス
  • 市場リーダー上位5社の市場収益分析
  • M&A・ジョイントベンチャー (該当する場合)
  • SWOT分析 (参入5社)
  • 特許分析 (該当する場合)

第11章 価格分析

第12章 ケーススタディ

第13章 主要企業の見通し

  • Roche Holdings AG
  • Siemens Healthineers AG
  • Myriad Genetics, Inc.
  • Thermo Fisher Scientific Inc.
  • Becton Dickinson and Company
  • AstraZeneca plc
  • F. Hoffmann-La Roche Ltd.
  • Koninklijke Philips N.V.
  • Biocept Inc
  • Agilent Technologies, Inc.

第14章 戦略的提言

第15章 当社について・免責事項

図表

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 2. Global Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 3. Global Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 4. Global Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 5. Global Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 6. Global Prostate Cancer Diagnostics Market Share (%), By Region, 2017-2031F
  • Figure 7. North America Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 8. North America Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 9. North America Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 10. North America Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 11. North America Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 12. North America Prostate Cancer Diagnostics Market Share (%), By Country, 2017-2031F
  • Figure 13. United States Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 14. United States Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 15. United States Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 16. United States Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 17. United States Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 18. Canada Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 19. Canada Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 20. Canada Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 21. Canada Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 22. Canada Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 23. Mexico Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 24. Mexico Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 25. Mexico Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 26. Mexico Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 27. Mexico Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 28. Europe Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 29. Europe Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 30. Europe Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 31. Europe Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 32. Europe Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 33. Europe Prostate Cancer Diagnostics Market Share (%), By Country, 2017-2031F
  • Figure 34. Germany Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 35. Germany Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 36. Germany Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 37. Germany Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 38. Germany Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 39. France Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 40. France Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 41. France Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 42. France Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 43. France Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 44. Italy Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 45. Italy Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 46. Italy Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 47. Italy Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 48. Italy Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 49. United Kingdom Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 50. United Kingdom Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 51. United Kingdom Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 52. United Kingdom Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 53. United Kingdom Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 54. Russia Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 55. Russia Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 56. Russia Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 57. Russia Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 58. Russia Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 59. Netherlands Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 60. Netherlands Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 61. Netherlands Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 62. Netherlands Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 63. Netherlands Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 64. Spain Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 65. Spain Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 66. Spain Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 67. Spain Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 68. Spain Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 69. Turkey Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 70. Turkey Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 71. Turkey Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 72. Turkey Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 73. Turkey Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 74. Poland Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 75. Poland Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 76. Poland Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 77. Poland Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 78. Poland Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 79. South America Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 80. South America Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 81. South America Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 82. South America Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 83. South America Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 84. South America Prostate Cancer Diagnostics Market Share (%), By Country, 2017-2031F
  • Figure 85. Brazil Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 86. Brazil Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 87. Brazil Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 88. Brazil Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 89. Brazil Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 90. Argentina Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 91. Argentina Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 92. Argentina Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 93. Argentina Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 94. Argentina Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 95. Asia-Pacific Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 96. Asia-Pacific Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 97. Asia-Pacific Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 98. Asia-Pacific Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 99. Asia-Pacific Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 100. Asia-Pacific Prostate Cancer Diagnostics Market Share (%), By Country, 2017-2031F
  • Figure 101. India Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 102. India Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 103. India Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 104. India Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 105. India Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 106. China Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 107. China Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 108. China Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 109. China Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 110. China Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 111. Japan Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 112. Japan Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 113. Japan Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 114. Japan Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 115. Japan Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 116. Australia Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 117. Australia Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 118. Australia Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 119. Australia Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 120. Australia Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 121. Vietnam Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 122. Vietnam Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 123. Vietnam Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 124. Vietnam Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 125. Vietnam Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 126. South Korea Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 127. South Korea Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 128. South Korea Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 129. South Korea Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 130. South Korea Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 131. Indonesia Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 132. Indonesia Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 133. Indonesia Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 134. Indonesia Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 135. Indonesia Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 136. Philippines Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 137. Philippines Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 138. Philippines Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 139. Philippines Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 140. Philippines Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 141. Middle East & Africa Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 142. Middle East & Africa Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 143. Middle East & Africa Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 144. Middle East & Africa Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 145. Middle East & Africa Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 146. Middle East & Africa Prostate Cancer Diagnostics Market Share (%), By Country, 2017-2031F
  • Figure 147. Saudi Arabia Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 148. Saudi Arabia Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 149. Saudi Arabia Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 150. Saudi Arabia Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 151. Saudi Arabia Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 152. UAE Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 153. UAE Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 154. UAE Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 155. UAE Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 156. UAE Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 157. South Africa Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 158. South Africa Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 159. South Africa Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 160. South Africa Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 161. South Africa Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 162. By Diagnostic Technique Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 163. By Cancer Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 164. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 165. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023
目次
Product Code: MX11090

Global prostate cancer diagnostics market is projected to witness a CAGR of 7.26% during the forecast period 2024-2031, growing from USD 6.31 billion in 2023 to USD 11.05 billion in 2031. The global prostate cancer diagnostics market is shaped by various factors. These include advancing technologies such as AI, an increase in investments, advantages of biomarker test offerings, tools for diagnosis of adenocarcinoma, and a rise in awareness of prostate cancer.

These factors are crucial for the growth and development of the market. Advancements in cutting-edge technologies, especially artificial intelligence (AI), play an important role in influencing the global prostate cancer diagnostics market. AI is responsible for the increasing speed and accuracy of diagnosis by analyzing large amounts of complex data for patterns that indicate prostate cancer.

Both public and private firms are heavily investing in the global prostate cancer diagnostics market. These investments are used for research and development purposes, which help in developing advanced solutions for the market. Often, public and private firms work together utilizing each other's strengths to spur innovation in the global prostate cancer diagnostics market. Hence, public private partnerships are often a successful model in the healthcare industry.

Another important aspect influencing the global prostate cancer diagnostics market is biomarker testing. By detecting a chemical in blood or tissue, biomarker testing provides important information that helps clinicians to make a diagnosis. Thus, due to the accuracy and reliability provided by biomarkers, they are considered important devices for early detection and monitoring of prostate cancer.

Significant developments have been made in the improvement of specialized instruments meant for the diagnosis of adenocarcinoma, the most common form of prostate cancer. By using these instruments, malignant cells in the prostate may be exactly identified and defined, taking into consideration extra-centered and successful remedy plans. It is a significant factor influencing the growth of global prostate cancer diagnostics market.

Consequently, there has been a tremendous impact from the increased expertise in prostate cancer. Higher screening quotes, early detection, and better remedy outcomes have resulted from elevated widespread public expertise and comprehension of the disorder. For instance, Astellas, a Japanese multinational pharmaceutical company, provided financing support for the Prostate Health Awareness and Screening Campaign (PHASC) in June 2023 with the support of MAP International. It is a multifaceted strategy aimed at increasing public knowledge of a malignancy that has been historically underrepresented in the Dominican Republic through the media.

Technological Advancements

The expansion of global prostate cancer diagnostics market is being significantly affected by advancing technologies specifically AI. The use of AI in diagnostic methods improves prostate cancer detection efficiency and accuracy. AI algorithms can detect certain signs of prostate cancer that may go unnoticed by the human eye by examining big datasets. It permits AI algorithms to diagnose cancer more quickly and appropriately than traditional strategies. The capability is crucial for early prognosis since it makes timely interventions that might save lives. As a result, using AI is causing a revolution inside the field of prostate cancer diagnostics, improving affected person outcomes and accelerating enterprise expansion.

Researchers at the UCLA Health Jonsson Comprehensive Cancer Center were awarded a three-year, USD 3 million grant by the National Cancer Institute in December 2023 to help prevent needless treatments and their unfavorable side effects. The goal of this grant is to identify novel cancer biomarkers and develop AI that can detect and predict aggressive prostate cancer.

Increase in Investments

The global prostate cancer diagnostics market receives funding from businesses and organizations to encourage the creation of new ideas. Access to funding is necessary to enable the development of new strategies for the detection of prostate cancer and technologies to enhance research and development efforts. Investments are being made to help develop new methods and improve upon existing methods, such as AI-powered diagnostic platforms and sophisticated biomarker tests which play an important role in driving the industry forward. Increased investments spur innovation and help in getting rid of the age-old technologies for diagnosing prostate cancer.

On 13th February, Macmillan Cancer Support announced their investment of GBP 350,100 in Pi, Lucida Medical's new AI platform, to improve the accuracy and efficiency of prostate cancer tests.

Advantages that the Biomarker Test Offers

Prostate cancer diagnosis is increasing exponentially mainly due to the growing demand for biomarker testing. Biomarker tests are the most commonly used methods and are becoming increasingly popular due to their numerous advantages. As these tests are highly sensitive and specific, they can identify the proteins or genes associated with prostate cancer. It allows for an immediate response that allows for early detection of the condition, even before symptoms appear. In addition, biomarker testing may enable the development of tailored treatment strategies by providing important information about cancer aggressiveness and responsiveness to treatment. Increasing demand is due to the efficiency and accuracy of biomarker testing for the detection and treatment of prostate cancer, emphasizing its importance in the global prostate cancer diagnostics market.

In July 2023, Quest Diagnostics announced the introduction of AmeriPath, a new prostate cancer biomarker test in association with Envision Sciences, which is its subspecialty pathology division. Envision Sciences Pty Ltd. is creating a pipeline of blood and tissue biomarker-based cancer diagnostic and predictive assays.

Tools for Diagnosis of Adenocarcinoma

The global prostate cancer diagnostics market is experiencing a surge, driven by the introduction of innovative instruments designed to detect its diverse forms, particularly the prevalent adenocarcinoma. These instruments leverage cutting-edge technologies like molecular diagnostics and advanced imaging, offering precise identification and characterization of adenocarcinomas. It translates to a significant clinical advantage. Armed with detailed information on tumor location, size, and extent, physicians can formulate highly targeted treatment plans, optimizing patient outcomes. These specialized diagnostic tools address a critical need for early and accurate detection, considered as a cornerstone of successful prostate cancer management.

Consequently, the launch of these instruments represents a strategic market mover, catering to the burgeoning demand for sophisticated diagnostic solutions. The development benefits patients through improved clinical outcomes and propels the industry forward by addressing a crucial unmet need. The advancements signify a positive trajectory for the prostate cancer diagnostics market, paving the way for enhanced patient care and industry growth.

Prostate cancer may be diagnosed by pathologists using QAi Prostate, a sophisticated artificial intelligence (AI) technology that was unveiled in March 2023 by Singapore-based healthtech startup Qritive. QAi Prostate uses sophisticated machine learning (ML) algorithms to reliably identify regions of prostatic adenocarcinoma and classify benign and malignant tumor locations in biopsy tissue samples.

North America to Dominate the Market

North America stands as the leader in the global prostate cancer diagnostics market. The region is expected to dominate due to its advanced healthcare system and the concerning rates of disease in specific populations. The region boasts a sophisticated healthcare infrastructure that fosters exhilarating innovation. It translates to intensified research, development, and adoption of cutting-edge diagnostic technologies, propelling the market forward at a rapid pace. Powerful tools like molecular diagnostics and advanced imaging empower early detection and more precise diagnosis. Also, the need for these advancements resonates deeply in communities disproportionately affected by the disease. Native American and Black men face alarmingly high prostate cancer rates, highlighting the urgent need for effective diagnostic methods. In North Carolina, prostate cancer sits as the second-highest cause of male cancer deaths, further underlining the criticality of early identification.

An interactive web application was introduced in December 2023 by Carolina Demography and The UNC Men's Health Programme to eliminate prostate cancer inequities in North Carolina and increase public awareness of the disease.

Future Market Scenario

Introduction of new biomarkers such as 4Kscore, TMPRSS2-ERG fusion, and PCA3 to diagnose prostate cancer correctly and with improved efficiency to spur the global prostate cancer diagnostics market in the future.

The increasing number of cases of adenocarcinoma will drive the growth of the global prostate cancer diagnostics market.

Patients preferring more cost-effective and personalized treatment options in the global prostate cancer diagnostics market will force the healthcare industry to adapt to more faster and convenient methods of diagnosis.

With new startups entering the global prostate cancer diagnostics market, there will be an outburst of new technological interventions to diagnose prostate cancer.

Key Players Landscape and Outlook

The global prostate cancer diagnostics market is witnessing a significant shift towards strategic partnerships between startups and small businesses. The collaborative approach allows these entities to surmount financial and technological hurdles that might otherwise impede their independent progress. By pooling resources, knowledge, and cutting-edge technologies, these alliances can significantly accelerate research and development activities, leading to the emergence of innovative diagnostic tools and techniques. Such partnerships create a dynamic and competitive market environment, fostering a culture of continuous innovation. The diversity of ideas and expertise brought together by these partnerships results in a broader spectrum of diagnostic solutions.

Leading AI-powered biopharmaceutical company BPGbio, Inc. has partnered with Grupo Terralpe, Inc. in July 2023. The businesses will collaborate to market BPGbio's prostate cancer diagnostic test, pstateDx, in Mexico.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Prostate Cancer Diagnostics Market Outlook, 2017-2031F

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
    • 4.1.2. By Volume
  • 4.2. By Diagnostic Technique
    • 4.2.1. Imaging Tests
      • 4.2.1.1. Ultrasound
      • 4.2.1.2. Positron Emission Tomography (PET) Scan
      • 4.2.1.3. Magnetic Resonance Imaging (MRI)
      • 4.2.1.4. Computerized Tomography (CT) Scan
      • 4.2.1.5. Bone Scan
    • 4.2.2. Biopsy
    • 4.2.3. Biomarker Tests
    • 4.2.4. Immunohistochemistry
    • 4.2.5. Others
  • 4.3. By Cancer Type
    • 4.3.1. Squamous Cell Carcinoma
    • 4.3.2. Small Cell Prostate Cancer
    • 4.3.3. Adenocarcinoma
    • 4.3.4. Transitional Cell Carcinoma
    • 4.3.5. Others
  • 4.4. By End-user
    • 4.4.1. Hospitals
    • 4.4.2. Cancer Research Institutes
    • 4.4.3. Diagnostic Centers
    • 4.4.4. Others
  • 4.5. By Region
    • 4.5.1. North America
    • 4.5.2. Europe
    • 4.5.3. Asia-Pacific
    • 4.5.4. South America
    • 4.5.5. Middle East and Africa
  • 4.6. By Company Market Share (%), 2023

5. Global Prostate Cancer Diagnostics Market Outlook, By Region, 2017-2031F

  • 5.1. North America*
    • 5.1.1. Market Size & Forecast
      • 5.1.1.1. By Value
      • 5.1.1.2. By Volume
    • 5.1.2. By Diagnostic Technique
      • 5.1.2.1. Imaging Tests
      • 5.1.2.1.1. Ultrasound
      • 5.1.2.1.2. Positron Emission Tomography (PET) Scan
      • 5.1.2.1.3. Magnetic Resonance Imaging (MRI)
      • 5.1.2.1.4. Computerized Tomography (CT) Scan
      • 5.1.2.1.5. Bone Scan
      • 5.1.2.2. Biopsy
      • 5.1.2.3. Biomarker Tests
      • 5.1.2.4. Immunohistochemistry
      • 5.1.2.5. Others
    • 5.1.3. By Cancer Type
      • 5.1.3.1. Squamous Cell Carcinoma
      • 5.1.3.2. Small Cell Prostate Cancer
      • 5.1.3.3. Adenocarcinoma
      • 5.1.3.4. Transitional Cell Carcinoma
      • 5.1.3.5. Others
    • 5.1.4. By End-user
      • 5.1.4.1. Hospitals
      • 5.1.4.2. Cancer Research Institutes
      • 5.1.4.3. Diagnostic Centers
      • 5.1.4.4. Others
    • 5.1.5. United States*
      • 5.1.5.1. Market Size & Forecast
      • 5.1.5.1.1. By Value
      • 5.1.5.1.2. By Volume
      • 5.1.5.2. By Diagnostic Technique
      • 5.1.5.2.1. Imaging Tests
      • 5.1.5.2.1.1. Ultrasound
      • 5.1.5.2.1.2. Positron Emission Tomography (PET) Scan
      • 5.1.5.2.1.3. Magnetic Resonance Imaging (MRI)
      • 5.1.5.2.1.4. Computerized Tomography (CT) Scan
      • 5.1.5.2.1.5. Bone Scan
      • 5.1.5.2.2. Biopsy
      • 5.1.5.2.3. Biomarker Tests
      • 5.1.5.2.4. Immunohistochemistry
      • 5.1.5.2.5. Others
      • 5.1.5.3. By Cancer Type
      • 5.1.5.3.1. Squamous Cell Carcinoma
      • 5.1.5.3.2. Small Cell Prostate Cancer
      • 5.1.5.3.3. Adenocarcinoma
      • 5.1.5.3.4. Transitional Cell Carcinoma
      • 5.1.5.3.5. Others
      • 5.1.5.4. By End-user
      • 5.1.5.4.1. Hospitals
      • 5.1.5.4.2. Cancer Research Institutes
      • 5.1.5.4.3. Diagnostic Centers
      • 5.1.5.4.4. Others
    • 5.1.6. Canada
    • 5.1.7. Mexico

All segments will be provided for all regions and countries covered

  • 5.2. Europe
    • 5.2.1. Germany
    • 5.2.2. France
    • 5.2.3. Italy
    • 5.2.4. United Kingdom
    • 5.2.5. Russia
    • 5.2.6. Netherlands
    • 5.2.7. Spain
    • 5.2.8. Turkey
    • 5.2.9. Poland
  • 5.3. Asia-Pacific
    • 5.3.1. India
    • 5.3.2. China
    • 5.3.3. Japan
    • 5.3.4. Australia
    • 5.3.5. Vietnam
    • 5.3.6. South Korea
    • 5.3.7. Indonesia
    • 5.3.8. Philippines
  • 5.4. South America
    • 5.4.1. Brazil
    • 5.4.2. Argentina
  • 5.5. Middle East & Africa
    • 5.5.1. Saudi Arabia
    • 5.5.2. UAE
    • 5.5.3. South Africa

6. Market Mapping, 2023

  • 6.1. By Diagnostic Technique
  • 6.2. By Cancer Type
  • 6.3. By End-user
  • 6.4. By Region

7. Macro Environment and Industry Structure

  • 7.1. Demand Supply Analysis
  • 7.2. Import Export Analysis
  • 7.3. Value Chain Analysis
  • 7.4. PESTEL Analysis
    • 7.4.1. Political Factors
    • 7.4.2. Economic System
    • 7.4.3. Social Implications
    • 7.4.4. Technological Advancements
    • 7.4.5. Environmental Impacts
    • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5. Porter's Five Forces Analysis
    • 7.5.1. Supplier Power
    • 7.5.2. Buyer Power
    • 7.5.3. Substitution Threat
    • 7.5.4. Threat from New Entrant
    • 7.5.5. Competitive Rivalry

8. Market Dynamics

  • 8.1. Growth Drivers
  • 8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

  • 9.1. Clinical Trials
  • 9.2. Patent Landscape
  • 9.3. Regulatory Approvals
  • 9.4. Innovations/Emerging Technologies

10. Key Players Landscape

  • 10.1. Competition Matrix of Top Five Market Leaders
  • 10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4. SWOT Analysis (For Five Market Players)
  • 10.5. Patent Analysis (If Applicable)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

  • 13.1. Roche Holdings AG
    • 13.1.1. Company Details
    • 13.1.2. Key Management Personnel
    • 13.1.3. Products & Services
    • 13.1.4. Financials (As reported)
    • 13.1.5. Key Market Focus & Geographical Presence
    • 13.1.6. Recent Developments
  • 13.2. Siemens Healthineers AG
  • 13.3. Myriad Genetics, Inc.
  • 13.4. Thermo Fisher Scientific Inc.
  • 13.5. Becton Dickinson and Company
  • 13.6. AstraZeneca plc
  • 13.7. F. Hoffmann-La Roche Ltd.
  • 13.8. Koninklijke Philips N.V.
  • 13.9. Biocept Inc
  • 13.10. Agilent Technologies, Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14. Strategic Recommendations

15. About Us & Disclaimer